CTLA4 promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma

Download full text files

Export metadata

Statistics

Number of document requests

Additional Services

Share in Twitter Search Google Scholar
Metadaten
Author:Niklas Klümper, Damian J. Ralser, Romina Zarbl, Katrin Schlack, Andres Jan Schrader, Marc Rehlinghaus, Michele J. Hoffmann, Günter Niegisch, Annemarie Uhlig, Lutz Trojan, Julie Steinestel, Ralph M. Wirtz, Danijel Sikikc, Markus Eckstein, Glen Kristiansen, Marieta Toma, Michael Hölzel, Manuel Ritter, Sebstian Strieth, Jörg Ellinger, Dimo Dietrich, Konrad Steinestel
URN:urn:nbn:de:bvb:384-opus4-892625
Frontdoor URLhttps://opus.bibliothek.uni-augsburg.de/opus4/89262
ISSN:2051-1426OPAC
Parent Title (English):Journal for ImmunoTherapy of Cancer
Publisher:BioMed Central
Place of publication:London
Type:Article
Language:English
Year of first Publication:2021
Publishing Institution:Universität Augsburg
Release Date:2021/09/21
Volume:9
Issue:8
First Page:e002949
DOI:https://doi.org/10.1136/jitc-2021-002949
Institutes:Medizinische Fakultät
Medizinische Fakultät / Universitätsklinikum
Medizinische Fakultät / Lehrstuhl für Urologie
Dewey Decimal Classification:6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Licence (German):CC-BY 4.0: Creative Commons: Namensnennung (mit Print on Demand)